Eye implant could replace monthly shots for blinding disease
NCT ID NCT05562947
First seen Sep 30, 2025 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This study tests a small, refillable implant placed in the eye that slowly releases medication for wet age-related macular degeneration (nAMD). It aims to see if refilling the implant every 24 weeks works as well as getting a standard eye injection every 4 weeks. About 68 Chinese patients who have already responded to standard treatment will take part. The main goal is to measure changes in vision over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Hospital
WITHDRAWNBeijing, 100730, China
-
Beijing Tongren Hospital
RECRUITINGBeijing, 100730, China
-
Eye Hospital, Wenzhou Medical University
RECRUITINGWenzhou, 325027, China
-
Peking Union Medical College Hospital
RECRUITINGBeijing, 100032, China
-
Qingdao Eye Hospital of Shandong First Medical University
RECRUITINGQingdao, 266109, China
-
Shanghai First People's Hospital
RECRUITINGShanghai, 200080, China
-
Shanxi Eye Hospital
RECRUITINGTaiyuan, 030002, China
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, 610072, China
-
The First Affiliated Hospital of China Medical University
RECRUITINGShenyang, 110001, China
-
The Second Affiliated Hospital of Harbin Medical University
RECRUITINGHarbin, 150081, China
-
Tianjin Medical University Eye Hospital
RECRUITINGTianjin, 300070, China
-
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITINGWuhan, 430030, China
-
West China Hospital, Sichuan University
RECRUITINGChengdu, 610041, China
-
Xi'an People's Hospital (Xi'an Fourth Hospital)
RECRUITINGXi'an, China
-
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
ACTIVE_NOT_RECRUITINGShanghai, 200092, China
-
Zhongshan Ophthalmic Center, Sun Yat-sen University
RECRUITINGGuangzhou, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ranibizumab delivered via a refillable eye implant (Port Delivery System)
What this could lead to
If successful, this implant could allow patients with wet AMD to receive treatment every 6 months instead of monthly injections, reducing clinic visits.
What could go wrong
This is a Phase 3 trial with only 68 participants, so results may not apply to all patients. The implant requires surgery and carries risks like infection or implant issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.